Vasodilator-stimulated phosphoprotein-deficient mice demonstrate increased platelet activation but improved renal endothelial preservation and regeneration in passive nephrotoxic nephritis.

Vasodilator-stimulated phosphoprotein (VASP), an actin cytoskeletal protein, is expressed in various cell types including renal cells. In vitro studies provide evidence for a role of VASP regarding platelet activation, cell adhesion, migration, and capillary formation. The in vivo role of VASP was investigated in experimental inflammatory renal disease. Kidneys of healthy VASP deficient (-/-) and wild-type (wt) mice were compared regarding morphology and functional parameters. Passive nephrotoxic nephritis was induced in 28 VASP -/- and 28 wt mice; kidneys were harvested; and tissues were analyzed by morphometric, immunohistochemical, and electron microscopic techniques on days 3, 7, 14, and 28. The time course of disease in VASP -/- mice differed substantially and biphasically from that in wt controls. Early on, VASP -/- mice demonstrated increased platelet influx associated with augmented glomerular and tubulointerstitial inflammation and sclerosis. Whereas renal disease continuously worsened up to day 28 in wt controls, renal disease in VASP -/- mice hardly progressed after day 3 as assessed by various injury indices. This long-term improvement of renal histology in VASP -/- compared with wt mice was associated with remarkable capillary preservation/regeneration up to day 28 mediated via an increased proliferative and a reduced apoptotic activity of VASP-negative peritubular endothelial cells. Despite an enhanced injury response early on, VASP -/- mice are protected from long-term progression of nephrotoxic nephritis, which is associated with improved renal endothelial cell preservation and regeneration.

[1]  U. Walter,et al.  Vasodilator-Stimulated Phosphoprotein Regulates Proliferation and Growth Inhibition by Nitric Oxide in Vascular Smooth Muscle Cells , 2004 .

[2]  H. Trachtman.  Nitric oxide and glomerulonephritis. , 2004, Seminars in nephrology.

[3]  J. Loureiro,et al.  Function and regulation of Ena/VASP proteins. , 2003, Trends in cell biology.

[4]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[5]  Richard J. Johnson,et al.  Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis , 2003, Current opinion in nephrology and hypertension.

[6]  U. Walter,et al.  Increased Spreading, Rac/p21-activated Kinase (PAK) Activity, and Compromised Cell Motility in Cells Deficient in Vasodilator-stimulated Phosphoprotein (VASP)* , 2002, The Journal of Biological Chemistry.

[7]  A. Ridley,et al.  Rho GTPases and the regulation of endothelial permeability. , 2002, Vascular pharmacology.

[8]  Kayla J Bayless,et al.  Molecular basis of endothelial cell morphogenesis in three‐dimensional extracellular matrices , 2002, The Anatomical record.

[9]  A. Hall,et al.  Rac regulates endothelial morphogenesis and capillary assembly. , 2002, Molecular biology of the cell.

[10]  B. Levi,et al.  Role of vasodilator‐stimulated phosphoprotein in protein kinase A‐induced changes in endothelial junctional permeability , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  L. Truong,et al.  Role of the microvascular endothelium in progressive renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  H. Schmidt,et al.  Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. , 2002, Molecular pharmacology.

[13]  Stepan Gambaryan,et al.  Distribution, cellular localization, and postnatal development of VASP and Mena expression in mouse tissues , 2001, Histochemistry and Cell Biology.

[14]  E. Ritz,et al.  Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers , 2001 .

[15]  Y. Sugisaki,et al.  Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. , 2001, The American journal of pathology.

[16]  J. Hughes,et al.  Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. , 2001, Journal of the American Society of Nephrology : JASN.

[17]  J. Hughes,et al.  Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. , 2001, Journal of the American Society of Nephrology : JASN.

[18]  U. Walter,et al.  Actin-based motility: stop and go with Ena/VASP proteins. , 2001, Trends in biochemical sciences.

[19]  K. Hruska,et al.  Rac Regulates Vascular Endothelial Growth Factor Stimulated Motility , 2001, Cell communication & adhesion.

[20]  T. Meinertz,et al.  Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction , 2000, Circulation research.

[21]  N. Brindle,et al.  Vasodilator-Stimulated Phosphoprotein Is Involved in Stress-Fiber and Membrane Ruffle Formation in Endothelial Cells , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  J. Wehland,et al.  Fyn-Binding Protein (Fyb)/Slp-76–Associated Protein (Slap), Ena/Vasodilator-Stimulated Phosphoprotein (Vasp) Proteins and the Arp2/3 Complex Link T Cell Receptor (Tcr) Signaling to the Actin Cytoskeleton , 2000, The Journal of cell biology.

[23]  B. Nieswandt,et al.  Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. , 2000, Blood.

[24]  J. Hughes,et al.  Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial cell proliferation following ureteric obstruction. , 1999, American journal of physiology. Renal physiology.

[25]  F. Marumo,et al.  Identification of an acid-activated Cl(-) channel from human skeletal muscles. , 1999, The American journal of physiology.

[26]  N. Janjić,et al.  VEGF(165) mediates glomerular endothelial repair. , 1999, The Journal of clinical investigation.

[27]  K. Knobeloch,et al.  Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Davis,et al.  Coordinate induction of the actin cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated phosphoprotein, and profilin during capillary morphogenesis in vitro. , 1999, Experimental cell research.

[29]  A. Aszódi,et al.  The vasodilator‐stimulated phosphoprotein (VASP) is involved in cGMP‐ and cAMP‐mediated inhibition of agonist‐induced platelet aggregation, but is dispensable for smooth muscle function , 1999, The EMBO journal.

[30]  D. McDonald,et al.  Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. , 1998, The American journal of pathology.

[31]  W. Couser,et al.  Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. , 1998, Kidney international.

[32]  D. Critchley,et al.  The focal adhesion phosphoprotein, VASP. , 1998, The international journal of biochemistry & cell biology.

[33]  Y. Sugisaki,et al.  Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. , 1997, The American journal of pathology.

[34]  W. Couser,et al.  Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. , 1997, The Journal of clinical investigation.

[35]  M. Zeier,et al.  Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  E. Ritz,et al.  Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  W. Couser,et al.  Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. , 1995, Kidney international.

[38]  C. Alpers,et al.  Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. , 1995, The American journal of pathology.

[39]  E. Berg,et al.  Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[40]  U. Walter,et al.  Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. , 1994, European journal of biochemistry.

[41]  A. E. El Nahas,et al.  Role of growth hormone in the development of experimental renal scarring. , 1991, Kidney international.

[42]  R. J. Johnson,et al.  Platelets in inflammatory glomerular injury. , 1991, Seminars in nephrology.

[43]  U. Heinzmann,et al.  Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. , 2004, Blood.

[44]  U. Walter,et al.  Platelet-vessel wall interactions, focal adhesions, and the mechanism of action of endothelial factors. , 1995, Agents and actions. Supplements.

[45]  E. Weibel.  Practical methods for biological morphometry , 1979 .